Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alfacalcidol
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $357.0 million
Deal Type : Divestment
Leo Pharma Sells Portfolio of Four Products to Cheplapharm
Details : The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.
Brand Name : One-Alpha
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 31, 2020
Lead Product(s) : Alfacalcidol
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $357.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?